SNY vs. ABT
Compare and contrast key facts about Sanofi (SNY) and Abbott Laboratories (ABT).
Performance
SNY vs. ABT - Performance Comparison
Loading graphics...
SNY vs. ABT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | -1.51% | 4.93% | 1.09% | 6.55% | 0.57% | 7.00% | 0.39% | 20.47% | 6.06% | 9.96% |
ABT Abbott Laboratories | -17.87% | 12.87% | 4.81% | 2.26% | -20.68% | 30.53% | 28.04% | 22.08% | 29.06% | 52.03% |
Fundamentals
SNY:
$116.50B
ABT:
$178.86B
SNY:
$3.18
ABT:
$3.73
SNY:
15.02
ABT:
27.45
SNY:
2.51
ABT:
4.04
SNY:
1.63
ABT:
3.43
SNY:
$46.72B
ABT:
$44.33B
SNY:
$33.79B
ABT:
$24.61B
SNY:
$12.68B
ABT:
$11.33B
Returns By Period
In the year-to-date period, SNY achieves a -1.51% return, which is significantly higher than ABT's -17.87% return. Over the past 10 years, SNY has underperformed ABT with an annualized return of 5.86%, while ABT has yielded a comparatively higher 11.33% annualized return.
SNY
- 1D
- -0.93%
- 1M
- 0.15%
- YTD
- -1.51%
- 6M
- -4.08%
- 1Y
- -8.27%
- 3Y*
- -0.31%
- 5Y*
- 3.35%
- 10Y*
- 5.86%
ABT
- 1D
- -0.28%
- 1M
- -10.29%
- YTD
- -17.87%
- 6M
- -22.56%
- 1Y
- -20.80%
- 3Y*
- 2.36%
- 5Y*
- -1.16%
- 10Y*
- 11.33%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SNY vs. ABT — Risk / Return Rank
SNY
ABT
SNY vs. ABT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SNY | ABT | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.30 | -0.90 | +0.60 |
Sortino ratioReturn per unit of downside risk | -0.23 | -1.10 | +0.87 |
Omega ratioGain probability vs. loss probability | 0.97 | 0.84 | +0.13 |
Calmar ratioReturn relative to maximum drawdown | -0.57 | -0.85 | +0.28 |
Martin ratioReturn relative to average drawdown | -1.12 | -2.13 | +1.01 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| SNY | ABT | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.30 | -0.90 | +0.60 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.14 | -0.05 | +0.19 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.25 | 0.48 | -0.23 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.41 | -0.20 |
Correlation
The correlation between SNY and ABT is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
SNY vs. ABT - Dividend Comparison
SNY's dividend yield for the trailing twelve months is around 4.63%, more than ABT's 2.34% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | 4.63% | 4.56% | 4.22% | 3.83% | 4.32% | 3.80% | 3.61% | 3.47% | 4.29% | 3.82% | 4.11% | 3.77% |
ABT Abbott Laboratories | 2.34% | 1.88% | 1.95% | 1.85% | 1.71% | 1.28% | 1.32% | 1.47% | 1.55% | 1.86% | 2.71% | 2.14% |
Drawdowns
SNY vs. ABT - Drawdown Comparison
The maximum SNY drawdown since its inception was -46.46%, smaller than the maximum ABT drawdown of -55.57%. Use the drawdown chart below to compare losses from any high point for SNY and ABT.
Loading graphics...
Drawdown Indicators
| SNY | ABT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -46.46% | -55.57% | +9.11% |
Max Drawdown (1Y)Largest decline over 1 year | -17.87% | -25.18% | +7.31% |
Max Drawdown (5Y)Largest decline over 5 years | -33.52% | -33.88% | +0.36% |
Max Drawdown (10Y)Largest decline over 10 years | -33.52% | -33.88% | +0.36% |
Current DrawdownCurrent decline from peak | -16.11% | -25.62% | +9.51% |
Average DrawdownAverage peak-to-trough decline | -12.15% | -14.29% | +2.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.06% | 10.05% | -0.99% |
Volatility
SNY vs. ABT - Volatility Comparison
Sanofi (SNY) has a higher volatility of 6.79% compared to Abbott Laboratories (ABT) at 5.96%. This indicates that SNY's price experiences larger fluctuations and is considered to be riskier than ABT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| SNY | ABT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.79% | 5.96% | +0.83% |
Volatility (6M)Calculated over the trailing 6-month period | 16.85% | 16.81% | +0.04% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.50% | 23.10% | +4.40% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.65% | 21.97% | +2.68% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.51% | 23.57% | -0.06% |
Financials
SNY vs. ABT - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and Abbott Laboratories. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNY vs. ABT - Profitability Comparison
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Sanofi reported a gross profit of 8.58B and revenue of 12.21B. Therefore, the gross margin over that period was 70.3%.
ABT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Abbott Laboratories reported a gross profit of 6.54B and revenue of 11.46B. Therefore, the gross margin over that period was 57.1%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Sanofi reported an operating income of -1.04B and revenue of 12.21B, resulting in an operating margin of -8.5%.
ABT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Abbott Laboratories reported an operating income of 2.25B and revenue of 11.46B, resulting in an operating margin of 19.6%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Sanofi reported a net income of -801.00M and revenue of 12.21B, resulting in a net margin of -6.6%.
ABT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Abbott Laboratories reported a net income of 1.78B and revenue of 11.46B, resulting in a net margin of 15.5%.